Skip to main content

Advertisement

SpringerLink
Log in

Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis, but the underlying mechanisms are unclear. The size and number of lipoprotein particles may be better predictors of atherosclerosis than conventional cholesterol measurements. We measured lipoprotein subclasses by nuclear magnetic resonance spectroscopy (NMR), coronary artery calcification by electron beam computed tomography, and insulin resistance by homeostasis model assessment in 105 patients with SLE and 77 control subjects. VLDL particles were larger (50.0 ± 8.5 versus 47.7 ± 8.5 nm, P = 0.01) and concentrations of large high-density lipoprotein (HDL) particles lower (10.1 ± 5.3 versus 11.3 ± 5.1 nmol/L, P = 0.03) in patients with SLE than controls. In patients with SLE, small LDL concentration was associated with body mass index (rho = 0.27), insulin resistance (rho = 0.34), C-reactive protein (CRP; rho = 0.30), and erythrocyte sedimentation rate (ESR; rho = 0.20); all P < 0.05. Large HDL concentration was inversely associated with insulin resistance (rho = −0.29), disease activity (rho = −0.23), and ESR (rho = −0.39); all P < 0.05. VLDL concentrations correlated with CRP (rho = 0.22), ESR (rho = 0.24), disease damage (rho = 0.20), and corticosteroid exposure (rho = 0.29); all P < 0.05. Neither the concentration of lipoprotein subclasses nor particle size was associated with coronary artery atherosclerosis. There were only minor differences in the NMR lipid profiles of patients with SLE and controls. Lipoprotein subclasses were associated with metabolic variables, inflammatory markers, and corticosteroid use but not with coronary artery atherosclerosis in SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Asanuma Y, Oeser A, Shintani AK et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 349(25):2407–2415

    Article  CAS  Google Scholar 

  2. Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Eng J Med 349(25):2399–2406

    Article  CAS  Google Scholar 

  3. Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145(5):408–415

    PubMed  CAS  Google Scholar 

  4. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42(2):338–346

    Article  PubMed  CAS  Google Scholar 

  5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22(7):1259–1264

    PubMed  CAS  Google Scholar 

  6. Grundy SM, Balady GJ, Criqui MH et al (1997) Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American heart association science advisory and coordinating committee. Circulation 95(9):2329–2331

    PubMed  CAS  Google Scholar 

  7. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC (2000) Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43(5):1033–1040

    Article  PubMed  CAS  Google Scholar 

  8. Borba EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6(6):533–539

    Article  PubMed  CAS  Google Scholar 

  9. Chung CP, Oeser A, Solus J et al (2007) Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol 34(9):1849–1854

    PubMed  CAS  Google Scholar 

  10. Carmena R, Duriez P, Fruchart JC (2004) Atherogenic lipoprotein particles in atherosclerosis. Circulation 109(23_suppl_1):III–2

    Article  CAS  Google Scholar 

  11. Rosenson RS, Otvos JD, Freedman DS (2002) Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am J Cardiol 90(2):89–94

    Article  PubMed  CAS  Google Scholar 

  12. Otvos JD, Jeyarajah EJ, Cromwell WC (2002) Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90(8, Supplement 1):22–29

    Article  Google Scholar 

  13. Blake GJ, Otvos JD, Rifai N, Ridker PM (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106(15):1930–1937

    Article  PubMed  CAS  Google Scholar 

  14. Kuller L, Arnold A, Tracy R et al (2002) Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22(7):1175–1180

    Article  PubMed  CAS  Google Scholar 

  15. Festa A, Williams K, Hanley AJG et al (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation 111(25):3465–3472

    Article  PubMed  Google Scholar 

  16. Kathiresan S, Otvos JD, Sullivan LM et al (2006) Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113(1):20–29

    Article  PubMed  CAS  Google Scholar 

  17. Chung CP, Avalos I, Oeser A et al (2007) High frequency of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66(2):208–214

    Article  PubMed  CAS  Google Scholar 

  18. Esteve E, Ricart W, Fernandez-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24(1):16–31

    Article  PubMed  CAS  Google Scholar 

  19. Asanuma Y, Chung CP, Oeser A et al (2006) Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33(3):539–545

    PubMed  CAS  Google Scholar 

  20. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52(11):3651–3659

    Article  PubMed  CAS  Google Scholar 

  21. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277

    Article  PubMed  CAS  Google Scholar 

  22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640

    Article  PubMed  CAS  Google Scholar 

  23. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363–369

    Article  PubMed  CAS  Google Scholar 

  24. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Vaimonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15(4):827–832

    Article  PubMed  CAS  Google Scholar 

  25. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25):3143–3421

    Google Scholar 

  26. Doria A, Shoenfeld Y, Wu R et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62(11):1071–1077

    Article  PubMed  CAS  Google Scholar 

  27. Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2(1):19–23

    Article  PubMed  CAS  Google Scholar 

  28. Svenungsson E, Jensen-Urstad K, Heimburger M et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104(16):1887–1893

    Article  PubMed  CAS  Google Scholar 

  29. Cederholm A, Svenungsson E, Stengel D et al (2004) Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 50(9):2869–2876

    Article  PubMed  CAS  Google Scholar 

  30. Selzer F, Sutton-Tyrrell K, Fitzgerald SG et al (2004) Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 50(1):151–159

    Article  PubMed  Google Scholar 

  31. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA (1998) Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 18(7):1046–1053

    PubMed  CAS  Google Scholar 

  32. Van Lenten BJ, Hama SY, de Beer FC et al (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96(6):2758–2767

    Article  PubMed  Google Scholar 

  33. McMahon M, Grossman J, Fitzgerald J et al (2006) Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54(8):2541–2549

    Article  PubMed  CAS  Google Scholar 

  34. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58(3):342–374

    Article  PubMed  CAS  Google Scholar 

  35. Lagogianni I, Papapanagiotou A, Piperi C et al (2005) Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus. Clin Biochem 38(3):286–290

    Article  PubMed  CAS  Google Scholar 

  36. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J et al (2004) High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 50(1):160–165

    Article  PubMed  CAS  Google Scholar 

  37. Mora S, Szklo M, Otvos JD et al (2007) LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192(1):211–217

    Article  PubMed  CAS  Google Scholar 

  38. Lyons TJ, Jenkins AJ, Zheng D et al (2006) Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima–media thickness. Diabet Med 23(9):955–966

    Article  PubMed  CAS  Google Scholar 

  39. Colhoun HM, Otvos JD, Rubens MB, Taskinen MR, Underwood SR, Fuller JH (2002) Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes 51(6):1949–1956

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by grants (HL04012, HL65082, and GM5M01-RR00095) from the National Institutes of Health and by a grant from the Lupus Foundation of America, Nashville Chapter. Dr. Ingrid Avalos is supported by a grant from the American College of Rheumatology.

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Medicine, Vanderbilt University, Nashville, TN, USA

    Cecilia P. Chung, Annette Oeser, Ingrid Avalos, MacRae F. Linton, Sergio Fazio & C. Michael Stein

  2. Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA

    Joseph F. Solus

  3. Department of Pathology, Vanderbilt University, Nashville, TN, USA

    Sergio Fazio

  4. Division of Clinical Pharmacology, 560 Robinson Research Building, Vanderbilt University School of Medicine, 23rd Ave S at Pierce Ave., Nashville, TN, 37232-6602, USA

    Cecilia P. Chung, Ingrid Avalos & C. Michael Stein

  5. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    Paolo Raggi

  6. Department of Pharmacology, Vanderbilt University, Nashville, TN, USA

    MacRae F. Linton

Authors
  1. Cecilia P. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Oeser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Raggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph F. Solus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ingrid Avalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. MacRae F. Linton
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sergio Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Michael Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Michael Stein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, C.P., Oeser, A., Raggi, P. et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 27, 1227–1233 (2008). https://doi.org/10.1007/s10067-008-0890-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-008-0890-4

Keywords

Search

Navigation